Compare AVO & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVO | DBVT |
|---|---|---|
| Founded | 1983 | 2002 |
| Country | United States | France |
| Employees | 3800 | 90 |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2020 | 2014 |
| Metric | AVO | DBVT |
|---|---|---|
| Price | $14.38 | $20.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $17.00 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 844.4K | 280.3K |
| Earning Date | 03-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.92 | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,391,200,000.00 | $5,636,000.00 |
| Revenue This Year | N/A | $79.21 |
| Revenue Next Year | $2.35 | $1,754.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.68 | ★ 35.77 |
| 52 Week Low | $9.60 | $6.49 |
| 52 Week High | $15.02 | $26.19 |
| Indicator | AVO | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 52.43 |
| Support Level | $11.60 | $20.23 |
| Resistance Level | $15.02 | $24.16 |
| Average True Range (ATR) | 0.52 | 1.12 |
| MACD | 0.18 | 0.11 |
| Stochastic Oscillator | 97.78 | 73.56 |
Mission Produce Inc produces, packs, and distributes mainly Hass avocados to retail, wholesale, and food service customers, offering pre-ripe and ripened fruit tailored to customer specifications through its network of ripening facilities. The Company operates through three segments: Marketing & Distribution, which sources and distributes fruit globally and generates the majority of revenue; International Farming, which owns and operates avocado orchards and supplies fruit mainly to Marketing & Distribution, with operations principally in Peru and Guatemala; and Blueberries, which farms blueberries sold under an exclusive marketing agreement. The Company's operations span Peru, the United States, Guatemala, Mexico, Europe, and Canada.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.